Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00219791
Status:
COMPLETED
Last Update Posted:
2014-09-11
First Post:
2005-09-15
Brief Title:
Study of Glucarpidase CPG2 for the Management of Patients With Delayed Methotrexate Clearance
Sponsor:
BTG International Inc
Organization:
BTG International Inc
Study Overview
Official Title:
Study of Recombinant Carboxypeptidase G2 CPG2 for the Management of Patients With Delayed Methotrexate MTX Clearance or Intrathecal MTX Overdosage
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate MTX clearance owing to MTX-induced renal failure following high-dose MTX therapy or with intrathecal MTX overdose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ek179-6 | None | None | None |